期刊文献+

进口和国产盐酸特拉唑嗪片的人体生物等效性研究 被引量:6

Study on bioequivalence of imported and domestic terazosin hydrochloride tablets in volunteers
下载PDF
导出
摘要 目的:比较进口和国产盐酸特拉唑嗪片剂药动学及人体生物等效性。方法:24名健康男性受试者随机交叉口服盐酸特拉唑嗪受试制剂和参比制剂2 mg,血浆样品经直接沉淀后,采用液相色谱-串联质谱(LC-MS/MS)法测定特拉唑嗪浓度,计算药动学参数。对主要药动学参数进行统计学分析,评价两制剂的生物等效性。结果:盐酸特拉唑嗪受试制剂和参比制剂主要药动学参数分别为:t1/2(9.55±1.19)和(9.95±1.45)h,tmax为(1.20±0.88)和(1.28±1.28)h,cmax为(57.59±16.61)和(57.12±17.83)ng/mL,AUC0~48为(621.96±152.54)和(607.52±126.03)ng.h.mL^-1,AUC0~∞为(640.81±156.06)和(628.52±127.69)ng.h.mL-1。受试制剂的相对生物利用度为(102.10±9.91)%。结论:盐酸特拉唑嗪受试制剂和参比制剂具有生物等效性。 Objective:To evaluate the pharmacokinetics and bioequivalence of imported and domestic terazosin hydrochloride tablets.Methods: Twenty-four healthy male volunteers were randomly administered a single crossover dose of 2 mg test and reference tablets.The concentrations of terazosin in plasma were determined by liquid chromatography-tandem mass spectrometry(LC-MS/MS) method after protein precipitation.The pharmacokinetic parameters of terazosin hydrochloride test and reference tablets were statistically calculated and the bioequivalence was evaluated. Results: The main pharmacokinetic paramcters of test and reference tablets were as follows: t1-2 (9.55±1.19) and (9.95±1.45) h,tmax (1.20±0.88) and (1.28± 1.28) h, cmax(57. 59 ±16.61) and (57.12±17.83) ng/mL, AUC0.48(621.96±152.54) and (607.52±126.03) ng.h.mL^-1. AUC0-∞, (640.81 ±156.06) and (628.52±127.69) ng.h.mL^-1,respectively. The relative bioavailability of test formulation was (102. 10±9.91 )Conclusion: The test tablets are bioequivalent to the reference tablets.
出处 《药学服务与研究》 CAS CSCD 2009年第5期370-373,共4页 Pharmaceutical Care and Research
基金 上海市科委科研计划项目(No.08411966700)
关键词 特拉唑嗪 生物等效性 色谱法 高压液相 质谱法 terazosin bioequivalence chromatography high pressure liquid mass spectrometry
  • 相关文献

参考文献5

二级参考文献30

  • 1钟大放.以加权最小二乘法建立生物分析标准曲线的若干问题[J].药物分析杂志,1996,16(5):343-346. 被引量:581
  • 2Gonzalez CM, McVary KT. The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia [J]. Curt Urol Rep, 2003 , 4 (4): 276. 被引量:1
  • 3Sugaya K, Kadekawa K, Ikehara A, et al. Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia [J] . Int J Urol. 2003 , 10 (11): 569. 被引量:1
  • 4Xu K, Wang X, Ling PM, Tsao SW , et al. The alphal - adrenoeeptor antagonist terazosin induces prostate cancer cell death through a p53 and Rb independent pathway [ J ] . Oncol Rep, 2003, 10 (5): 1555. 被引量:1
  • 5Gonzalez CM, McVary KT. The role tff combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia [J]. Curt Urol Rep, 2003, 4 (4): 276. 被引量:1
  • 6Johnson TM , Jones K, Williford WO, et al. Changes in nocturia from medical treatment of benign prostatic hypexplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial[J] . J Urol, 2003, 170 (1): 145. 被引量:1
  • 7蔡松良,中华泌尿外科杂志,1993年,14卷,323页 被引量:1
  • 8顾方六,中华泌尿外科杂志,1992年,13卷,462页 被引量:1
  • 9Cheah PY, Yuen KH, Liong ML. Improved high-performance liquid chromatographic analysis of terazosin in human plasma[J].J Chromatngr B, 2000, 745(2) : 439. 被引量:1
  • 10Sekhar EC, Rao TR, Sekhar KR, et al. Detennination of terazosin in human plasma, using high-performance liquid chromatography with fluorescence detection[J].J Chromarogr R. 1998, 710(1-2) : 137. 被引量:1

共引文献17

同被引文献37

引证文献6

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部